News | Mammography | October 11, 2018

iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology

Results demonstrate improvements in clinical performance and reading times

iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology

October 11, 2018 — iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software, demonstrating significant positive results for clinical performance and workflow efficiency. The findings confirmed that the latest artificial intelligence (AI) software solution to support DBT increased improvements in both reader sensitivity (8 percent on average) and specificity (6.9 percent on average). In addition, when reading tomosynthesis cases with the solution, radiologists’ reading times were reduced by more than half (52.7 percent on average).

“iCAD’s unique technology assists me in detecting more cancers, reassures me of my findings, and helps me concentrate on the essential work of a radiologist. The product reduced my reading time by approximately 50 percent, allowing me to read these cases in nearly the same amount of time as 2-D mammograms. I consider it to be one of the greatest tools in modern radiology,” said Axel Gräwingholt, M.D., Radiologie am Theater, Paderborn, Germany.

iCAD’s high-performance, concurrent read, cancer detection and workflow solution for breast tomosynthesis delivers benefits to both radiologists and their patients. The new technology is trained to detect malignancies and determine the probability of malignant findings, providing radiologists with a “certainty of finding” score for each case and each detected lesion. These scores represent the algorithm’s confidence that the detected soft tissue densities (masses, architectural distortions and asymmetries) and calcifications are malignant.

iCAD’s AI technology is available for use with leading digital breast tomosynthesis systems in Europe. The solution is pending clearance by the U.S. Food and Drug Administration (FDA).

The company will showcase its latest innovations in cancer detection at The European Society of Breast Imaging annual meeting, Oct. 11-13 in Athens, Greece.

For more information: www.icadmed.com

Related Content

Exo Imaging Raises $35 Million for Developmental Ultrasound Platform
News | Ultrasound Imaging | August 23, 2019
Exo Imaging Inc. announced a $35 million Series B financing round for its high-performance ultrasound platform based on...
Philips Signs Agreement to Create Taiwan's First Fully Digitalized Pathology Department
News | Digital Pathology | August 23, 2019
Philips announced that Taipei Veterans General Hospital (TPVGH) will utilize the Philips IntelliSite Pathology Solution...
Glassbeam Introduces AI-powered Rules and Alerts Engine for Clinsights
News | Analytics Software | August 23, 2019
Glassbeam Inc. revealed several technology enhancements in its Rules & Alerts engine that make it dramatically...
Sectra Signs Enterprise Imaging Contract With Vanderbilt Health
News | Enterprise Imaging | August 21, 2019
Sectra will install its enterprise imaging picture archiving and communication system (PACS) and vendor neutral archive...
Vaping Impairs Vascular Function

Image courtesy of the American Heart Association

News | Magnetic Resonance Imaging (MRI) | August 21, 2019
Inhaling a vaporized liquid solution through an e-cigarette, otherwise known as vaping, immediately impacts vascular...
Videos | Treatment Planning | August 21, 2019
This is an example of the Mirada DLCExpert deep learning software that automatically identifies organs, segments and
Jackson Memorial Hospital Holds Ribbon-cutting for New Cardiac Catheterization Labs
News | Angiography | August 21, 2019
Jackson Memorial Hospital in Miami celebrated the opening of two newly renovated cardiac catheterization suites during...
Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...